Prevention of type 1 diabetes by gene therapy
- PMID: 15467836
- PMCID: PMC518667
- DOI: 10.1172/JCI22103
Prevention of type 1 diabetes by gene therapy
Abstract
The autoimmune disease type 1 diabetes in humans and NOD mice is determined by multiple genetic factors, among the strongest of which is the inheritance of diabetes-permissive MHC class II alleles associated with susceptibility to disease. Here we examined whether expression of MHC class II alleles associated with resistance to disease could be used to prevent the occurrence of diabetes. Expression of diabetes-resistant MHC class II I-Abeta chain molecules in NOD mice following retroviral transduction of autologous bone marrow hematopoietic stem cells prevented the development of autoreactive T cells by intrathymic deletion and protected the mice from the development of insulitis and diabetes. These data suggest that type 1 diabetes could be prevented in individuals expressing MHC alleles associated with susceptibility to disease by restoration of protective MHC class II expression through genetic engineering of hematopoietic stem cells.
Figures
Comment in
-
Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity.J Clin Invest. 2004 Oct;114(7):892-4. doi: 10.1172/JCI23168. J Clin Invest. 2004. PMID: 15467826 Free PMC article.
References
-
- Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 1995;13:179–200. - PubMed
-
- Nepom GT, Kwok WW. Molecular basis for HLA-DQ associations with IDDM. Diabetes. 1998;47:1177–1184. - PubMed
-
- McDevitt H. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr. Opin. Immunol. 1998;10:677–681. - PubMed
-
- Ilonen J, et al. Estimation of genetic risk for type 1 diabetes. Am. J. Med. Genet. 2002;115:30–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
